---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029065"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:05:40.785940+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC

## Summary
- 64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).
- Raised $40M oversubscribed registered direct offering; cash runway extended into Q1 2027.
- Full-year 2024 net cash used $37.7M; operating expenses $49.3M, up $3.4M YoY.
- USPTO issued patent for onvansertib + bev in bev-naïve KRAS-mut mCRC, expiring no earlier than 2043.
- Additional CRDF-004 clinical data expected in 1H 2025.

## SEC filing metadata
- accession: 0000950170-25-029065
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/0000950170-25-029065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/crdf-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029065
- JSON: https://secwatch.observer/filing/0000950170-25-029065.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.